CTSONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Cytosorbents Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.96+0.85 (+20.68%)
Close on Oct 19, 2026
- Market cap
- $311.52M
- P/E (TTM)
- –
- Dividend yield
- –
Cytosorbents Corp revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total product sales | – | – | – | – | – | – | – | $33.79M | $32.93M | $32.16M | $31.08M | $31.38M | – | – |
| Other product sales | – | – | – | – | – | – | – | $77.05K | $95.46K | $90.64K | $69.69K | $300.79K | – | – |
| Government grants | – | – | – | – | – | – | – | $3.95M | $4.23M | $4.52M | $5.26M | $5.69M | – | – |
| CytoSorb sales | – | – | – | – | – | – | – | $33.72M | $32.84M | $32.07M | $31.02M | $31.08M | – | – |
By region
From the segment and revenue-disaggregation notes of Cytosorbents's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.